Metrics as of 10/14/2026, 11:43 AM (Berlin time), refresh in progress.
Ascentage Pharma Group International Stock
Ascentage Pharma Group International
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- CEO
- Dajun Yang
- Employees
- 767
- Market cap
- $1.4 B
- IPO
- 24/01/2025
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology company operating within the healthcare sector. Founded in 2009, the firm focuses primarily on clinical-stage development, aiming to discover and advance therapeutic solutions for various medical conditions, including several types of…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Ascentage Pharma Group International stock: price history
1D
-1.3%
1W
-0.5%
1M
-9.4%
6M
-45.1%
YTD
-43.3%
1Y
-57.6%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
31/03/2027 (in 165 days)
Volatility around earnings
~53% stronger price swings than usual
Ask the agents about Ascentage Pharma Group International
Analyst assessment of Ascentage Pharma Group International
PRICE TARGET LOW
US$40.00
CONSENSUS
US$40.00
MEDIAN
US$40.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 08/10/2026
Ascentage Pharma Group International stock metrics
P/E
-6.49
P/B
16.98
EV/EBITDA
-7.39
RETURN ON EQUITY
-145.1%
NET MARGIN
-270.2%
DEBT/EQUITY
3.76
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
28.4%
FLOAT SHARES
6,596,448
AVG. DAILY VOLUME (30D)
6,526
Insider transactions (SEC)
Yang Dajun
Yang Dajun
Zhai Yifan
Zhai Yifan
Institutional holders
Comparable stocks
Frequently asked questions about Ascentage Pharma Group International stock
What does Ascentage Pharma Group International do?
Ascentage Pharma Group International is a company in the Healthcare sector, Biotechnology industry, headquartered in China.
The CEO is Dajun Yang, the company employs around 767 people.
The IPO was on 24/01/2025; the stock trades on NASDAQ under the ticker AAPG.
What do analysts say about Ascentage Pharma Group International stock?
2 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$40.00, ranging from US$40.00 to US$40.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
When does Ascentage Pharma Group International report next?
The next earnings date is 31/03/2027.
Around past earnings, price swings were roughly 53% stronger than usual.
Does Ascentage Pharma Group International pay a dividend?
No, Ascentage Pharma Group International currently does not pay a dividend.
Which stocks are comparable to Ascentage Pharma Group International?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Ascentage Pharma Group International stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ascentage Pharma Group International against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.